Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sunvozertinib (DZD9008)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dizal Pharma

Drug class:

EGFR inhibitor, HER2 inhibitor, BTK inhibitor

Related drugs:

‹

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ibrutinib (172)

zanubrutinib (42)

acalabrutinib (33)

orelabrutinib (17)

pirtobrutinib (10)

cetuximab (317)

osimertinib (240)

erlotinib (229)

gefitinib (183)

panitumumab (114)

lapatinib (105)

neratinib (102)

brigatinib (45)

aumolertinib (22)

amivantamab-vmjw (15)

furmonertinib (11)

mobocertinib (7)

tarloxotinib bromide (7)

nimotuzumab (5)

rociletinib (5)

tomuzotuximab (4)

necitumumab (2)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

befotertinib (1)

trastuzumab (369)

trastuzumab-pkrb (23)

margetuximab (18)

poziotinib (16)

trastuzumab-dttb (11)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Zercepac (trastuzumab biosimilar) (7)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

pertuzumab/trastuzumab/hyaluronidase-zzxf (2)

Hercease (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ibrutinib (172)

zanubrutinib (42)

acalabrutinib (33)

orelabrutinib (17)

pirtobrutinib (10)

›

EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: B - Late Trials DZD9008 Sensitive : B	DZD9008 Sensitive: B - Late Trials DZD9008 Sensitive : B
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2